My 2 cents With vaccine rollout, immunity monitoring will be used to determine whether the vaccine is effective, for how long, and when it is time for a booster. Monitoring will likely continue for many years throughout the world, even after widespread vaccination. The most widely used antibody tests on the market do not specifically identify neutralizing antibodies. Instead, they measure a large family of antibodies that bind to various parts of the virus, but not necessarily neutralize it. To address this shortcoming, MedMira has developed a neutralizing antibody test which can effectively pinpoint antibodies with the blocking capability, thus serving as a powerful tool for the qualitative assessment of the antibody status pre- and post-vaccination.
Some investors will recognize the looming transition from widespread diagnosis of an active virus (PCR, Antigen) to widespread detection of immunity. Medmira’s test is based on its patented Rapid Vertical Flow (RVF) technology—a technology that has already achieved regulatory approvals in Canada, the US, Europe and China—and, which happens to be the fastest antibody test on the market with results that don’t disappear. Even big players like Roche cannot compete on the speed and accuracy of Medmira’s rapid diagnostics. The news release on Jan 29th wasn’t for investors, it was to alert big pharma that Medmira has developed a game-changing test that will be crucial for years to come. I’m not saying this is a sure thing by any means (obviously there’s risk) but on a risk/reward basis, I like where I stand in my investment with MIR.